Dr. Ravi

• 2017–present; Professor of Medicine, Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto
• 2009–present; Associate Member, Institute of Medical Sciences, University of Toronto, Toronto
• 2006–present; Clinician-Scientist, Division of Endocrinology and Metabolism, Department of Medicine, Mount Sinai Hospital, Sinai Health, Toronto

Former appointments 

• 2012–2017; Associate Professor, Division of Endocrinology and Metabolism, University of Toronto, Toronto
• 2006–2012; Assistant Professor, Division of Endocrinology and Metabolism, University of Toronto, Toronto 

• FRCPC, University of Toronto, Toronto; 1999–2003
• MD, University of Toronto, Toronto; 1994–1999
• MSc, University of Toronto, Toronto; 1992–1994
• BMath, University of Toronto, Toronto; 1987–1992

• 2022 – International Diabetes Federation (IDF) Diabetes in Women Award  
• 2020 – Fellow of the Canadian Academy of Health Sciences (CAHS)
• 2014 – Joe Doupe Young Investigator Award, Canadian Society of Clinical 
            Investigation (CSCI)
• 2013 – Dr. Charles Hollenberg Young Investigator Award, Canadian Society of  
            Endocrinology and Metabolism (CSEM) 

This research program consists of the following studies: 

Toronto Gestational Glucose Tolerance Cohort 

In this long-term prospective observational cohort study, women across the full spectrum of glucose tolerance in pregnancy (from normal glucose tolerance to mild dysglycemia to gestational diabetes (GDM)) are being followed with serial cardiometabolic characterization for over a decade after delivery to study early events in the natural history of type 2 diabetes (T2DM) and cardiovascular disease.

Funded by the Canadian Institutes of Health Research (CIHR). 

Preconception Cohort 

In this prospective observational cohort study that is taking place in China, a cohort of women previously recruited prior to their first pregnancy are undergoing cardiometabolic characterization, along with their partners and their children, a decade after delivery to evaluate the relationships between preconception maternal and paternal health and offspring development at 10 years of age. 

Funded by the Canadian Institutes of Health Research (CIHR). 

HeLTI GDM South Africa

This randomized controlled trial that is taking place in South Africa seeks to determine if preconception lifestyle intervention can reduce the incidence of GDM in young women.

Learn more about HeLTI South Africa trial.

Funded by the Canadian Institutes of Health Research (CIHR). 

HeLTI GDM Canada 

This randomized controlled trial that is taking place across Canada seeks to determine if preconception lifestyle intervention can reduce the incidence of GDM in young women.

Learn more about HeLTI Canada trial. 

Funded by the Canadian Institutes of Health Research (CIHR). 

HeLTI GDM India 

This randomized controlled trial that is taking place in India seeks to determine if preconception lifestyle intervention can reduce the incidence of GDM in young women. 

Learn more about HeLTI India trial.  

Funded by the Canadian Institutes of Health Research (CIHR). 

Elucidation of the individualized response to an 8-year lifestyle intervention aimed at reducing cardiometabolic risk in young women before, during and after pregnancy 

This team grant seeks to evaluate the lipidomic, metabolomic and proteomic determinants of the impact of peripartum lifestyle intervention on the risk of women developing pre-diabetes or diabetes within the first 5-years after pregnancy.

Funded by the Canadian Institutes of Health Research (CIHR). 

Biomarkers of Beta-cell Function (Diabetes Canada)

In this proteomic profiling study, we seek to identify biomarkers of the reversibility of beta-cell dysfunction and the capacity for sustained preservation of function over 2 years in early type 2 diabetes. 
 
Funded by Diabetes Canada.